Cystic fibrosis carrier frequency and estimated prevalence of the disease in Morocco  by Ratbi, Ilham et al.
(2008) 440–443
www.elsevier.com/locate/jcfJournal of Cystic Fibrosis 7Cystic fibrosis carrier frequency and estimated prevalence
of the disease in Morocco
Ilham Ratbi a,b, Emmanuelle Génin c, Marie Legendre a, Annick Le Floch a, Catherine Costa a,
Souad Cherkaoui-Deqqaqi b, Michel Goossens a, Abdelaziz Sefiani b, Emmanuelle Girodon a,⁎
a Service de Biochimie et Génétique, AP-HP et INSERM U841 équipe 11, groupe hospitalier Henri Mondor-Albert Chenevier, 94010 Créteil, France
b Département de Génétique Médicale, Institut National d'Hygiène, 27, avenue Ibn Batouta, BP 769, 11400 Rabat, Morocco
c INSERM UMR_S535, Université Paris Sud, 94817 Villejuif, France
Received 13 November 2007; received in revised form 26 December 2007; accepted 31 December 2007
Available online 1 February 2008Abstract
Background: The epidemiology of cystic fibrosis (CF) is poorly known in North African populations, in particular in Morocco and the CF carrier
frequency in the general Moroccan population has never been evaluated.
Methods: To estimate the prevalence of CF mutations in Morocco, blood samples from 150 healthy Moroccans were tested for frequent CFTR
mutations and the intron 8 polyT variant.
Results: Two subjects were heterozygous for F508del and eight others for the (T)5 variant.
Conclusion: These findings indicate that the Moroccan population is at risk for CF and CFTR-related disorders. CF prevalence could be in the
range of that found in European populations. Wider studies are necessary to identify the clinical pattern and accurately determine the prevalence
and molecular basis of CF in Morocco.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CF epidemiology; CF prevalence; Cystic fibrosis; Morocco1. Introduction
Cystic fibrosis transmembrane conductance regulator
(CFTR) gene (MIM⁎602421) mutations are associated with a
broad range of phenotypes, from severe classical cystic fibrosis
(CF) to CFTR-related disorders, such as isolated male infertility
by congenital bilateral absence of the vas deferens (CBAVD),
disseminated bronchiectasis and chronic pancreatitis. Over
1500 CFTR sequence changes have been described, F508del
being the most frequent mutation, along with geographic and
ethnic variations in their distribution and frequency [1,2]. Little
is known about the spectrum and frequency of CFTR gene⁎ Corresponding author. Emmanuelle Girodon. Service de Biochimie et
Génétique, Hôpital Henri-Mondor, 94010 Créteil, France. Tel.: +33 1 49 81 28 57;
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doi:10.1016/j.jcf.2007.12.006mutations in North African populations: data are available on
CF patients living in Algeria and Tunisia [3-5] and on CF
Moroccan patients living in Europe [1,6]. To our knowledge,
there is no data on the prevalence of CF mutations among the
native Moroccan population.
We carried out a preliminary study by screening healthy
Moroccan individuals for 32 CFTR gene mutations. From the
CF mutation frequency estimates obtained on this sample, we
determined the probable range of CF prevalence in Morocco.
2. Patients and methods
2.1. Patients
Blood samples were collected from 150 unrelated healthy
Moroccan volunteers, 71 males and 79 females, aged 18 to
55 years, who were recruited during a blood donation pro-
gramme at the Department of Medical Genetics of the Institutd by Elsevier B.V. All rights reserved.
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different regions of Morocco and confirmed the Moroccan
origin of their parents and grand-parents. They had no
discernable symptoms suggestive of CF. The study was
approved by the local ethics committee (Institut National
d'Hygiène, Rabat) and written consent to the genetic study was
obtained from all subjects.
2.2. Methods
Genomic DNAwas extracted from blood samples using a salt
extraction method [7]. We screened for 32CFTR gene mutations
(G85E, 394delTT, R117H, 621+1GNT, 711+1GNT, R334W,
R347P, R347H, 1078delT, A455E, I507del, F508del, V520F,
1717-1GNA, G542X, G551D, R553X, R560T, S549R(TNG),
S549N, 1898+1GNA, 2183AANG, 2184delA, 2789+5GNA,
3120 + 1G NA, R1162X, 3659delC, 3849 + 10kbC NT,
W1282X, 3905insT, 3876delA, N1303K) and the (T)5 splicing
variant of intron 8, using a commercial kit (CF v3 Genotyping
Assay, Abbott, Rungis, France).
The presence of F508del was confirmed using denaturing
gradient gel electrophoresis of exon 10 [8]. Whenever the (T)5
variant of intron 8 was detected, determination of the (TG)m(T)n
haplotype was performed using a validated fluorescent PCR
assay (manuscript submitted).
Allele frequencies and 95% Confidence Interval (CI) were
obtained by allele counting. The expected frequency of
homozygotes for a given mutation (M) in a population (P) was
obtained by using the Wright formula [9]:
P MMð Þ ¼ p 2 þ Fp 1 pð Þ ð1Þ
where p is prevalence of the mutation and F the mean inbreeding
coefficient of population. We considered 25% of marriages
between relatives with a large majority between first-cousins in
the Moroccan population, based on available regional data [10].
Given that the inbreeding coefficient of a first-cousin offspring is
1/16, a rough estimate of the mean inbreeding coefficient in the
Moroccan population will thus be 1/64≈0.015.
From the observed CF mutation frequency in our sample, an
estimate of the expected prevalence of CF in the Moroccan
population was obtained by using the following formula:
prevCF ¼ Fp1 þ 1 Fð Þp 21 þ 2p1p2 þ p 22 ð2Þ
where F is the inbreeding coefficient, p1 the prevalence of allele
F508del in our sample and p2 the estimated prevalence of all
non F508del CF alleles in the population. An estimate of p2 can
be obtained from p1 and the proportion PF508del of F508del
alleles among all CF alleles:
p2= (1−PF508del)×p1 /PF508del· PF508del is unknown in the
native Moroccan population but estimates can be found in the
literature. Note that in Eq. (2), inbreeding only increases the
frequency of F508del homozygotes. It probably also has an
impact on other CF mutations but to account for it, individual
estimates of the frequencies of all non F508del CF mutations in
the population will be needed.3. Results
Two men aged 32 and 43 years were found to be carriers for
F508del. These results were given individually within the
framework of a genetic counselling session. The carrier frequency
for F508del was 1/75, i.e. 1.3% with a 95% Confidence Interval
(CI) ranging from 0 to 3%, and the F508del allelic prevalencewas
1/150 (0.7%with a 95%CI ranging from 0 to 1.6%). No other CF
mutation was found in our population sample.
Apart from the two F508del carriers, eight other subjects
(5.3%) were heterozygous for the (T)5 variant and the estimated
allelic prevalence of this variant was thus 2.7% with a 95% CI
ranging from 0.8 to 4.5%. Four of these eight subjects carried
the (TG)12 allele in association with the (T)5 variant and four
carried the (TG)11 allele.
4. Discussion
4.1. Estimate of CF prevalence in the native Moroccan population
The epidemiology of CF in Morocco is poorly documented
compared to its neighboursAlgeria andTunisia, probably because
of misdiagnosis of the disease and lack of genetic studies. No data
is available on CF prevalence in the country and the CFTR
molecular pathology has not been studied in the native Moroccan
population. The populations of these countries are quite closed:
the main ethnic groups are the Berbers and Arabs, but there have
also been currents of Phoenicians, Romans, Vandals, Byzantines,
Turks, Moriscos, sub-Saharian Africans, and European remnants
of the colonial period [3]. Unfortunately, we had no information
about the precise ethnic origin of the 150 studied Moroccan
individuals but, as they originated from different regions of
Morocco, we have assumed that the cohort was fairly rep-
resentative of the overall Moroccan population. Despite the
limited size of the study population, our results document the
presence of CF alleles in this population. Drawing the pedigrees
with the names of relatives of the two F508del carriers clearly
indicated that they were unrelated. It could also be argued that
they might not be representative of the native Moroccan
population and could be of recent European origin. This cannot
be definitely ruled out. However, as with the other individuals
included in this study, the Moroccan origin of their parents and
grand-parents was clearly established.
Based on the F508del allelic prevalence of 1/150 and a
coefficient of inbreeding of 0.015, the expected frequency of
F508del homozygosity would thus be:
1=22; 500þ 0:015 1=150 149=150c 1
7000
To estimate the prevalence of CF, one needs to take into
account the proportion of F508del alleles among all CF alleles,
which is unknown in the native Moroccan population. Cal-
culations were thus made based on published data from studies
in CF patients (Table 1). In the first Tunisian and Algerian
studies of 10 and 39 CF patients, respectively, the proportion of
F508del was found quite similar: 17.9% and 20.0% of CFTR
alleles, respectively [3,5]. In a larger Tunisian cohort, Messaoud
Table 1
Estimated prevalences of non F508del alleles (p2) and of CF (prevCF) in the
Moroccan population, based on F508del allelic prevalence found in our
population sample (p1) and on published F508del proportion among CF alleles
(PF508del) in different Mediterranean populations
Literature data Estimates
Populations studied
(Reference)
Number
of
studied
CF
alleles
Published
proportion
of F508del
among CF
alleles
(PF508del)
Estimated
prevalence of
non F508del
alleles in the
Moroccan
population
(p2)
a
Estimated
prevalence
of CF in the
Moroccan
population
(prevCF)
b
Algerians
(Loumi et al., 1999)
20 0.20 1/37.5 1/820
North-African migrants
(Estivill et al., 1997)
147 0.30 1/64 1/1680
(Claustres et al., 2000) 158
Moroccan migrants
(Estivill et al., 1997)
Nd 0.40 1/100 1/2650
Portuguese
(Estivill et al., 1997)
454 0.45 1/123 1/3140
Tunisians
(Messaoud et al., 2005)
540 0.51 1/156 1/3700
Spanish
(Alonso et al., 2007)
1954 0.52 1/162 1/3790
Greeks
(Kanavakis et al., 2003)
874 0.53 1/169 1/3880
South Italians
(Castaldo et al., 2005)
392 0.56 1/191 1/4150
ap2=(1−PF508del)×p1 /PF508del.
e.g.: PF508del=40% (Estivill et al., 1997), p1=1/150, p2=0.60×1/150/0.40=1/100.
bprevCF=Fp1+ (1−F)p12+2p1p2+p22 ; F: inbreeding coefficient.
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alleles [4]. This proportion is closer to those reported in Southern
European populations such as Portuguese (44.5%) [1], Spanish
(51.7%) [11], Greek (53.4%) [12] and South Italian (55.6%) [13]
populations. Two large studies reported on CF molecular
epidemiology in North African patients living in Europe. In the
collaborative study of Estivill et al., F508del was found in 32% of
147 alleles and, more specifically, in 40% of CF alleles in
Moroccan patients [1]. However, the number of Moroccan CF
alleles was not mentioned. In the French collaborative study,
F508del accounted for 31% of 158 CF alleles in French patients
originating from North Africa (Morocco, Algeria, Tunisia) [6].
Beside F508del, other frequent mutations were found among
North African populations, in particular 711+1GNT, W1282X,
N1303K, G542X and R1162X [1,4,6]. The absence of these other
CFmutations in our study could be explained either by the limited
size of our population sample, the presence of mutations which
are not detected by the assay used, or a higher proportion of
F508del among CF alleles. Despite the common variety of origins
for North Africans, we suppose that each population is a particular
melting-pot of local and migrant populations and probably
possesses its own mutation repertoire that would be interesting to
investigate by larger clinical and molecular studies.
From our results in 150 healthy Moroccan individuals and
based on a range of proportion of F508del alleles of 30 to 56% and
an inbreeding coefficient of 0.015, the prevalence of CF inMorocco would range from 1/1680 to 1/4150. Considering the
effect of consanguinity for other mutations would further increase
the figures.Although such figuresmay be overestimated, possibly
because of a sample size effect, they suggest that CF prevalence in
Morocco reaches that found in European populations.
4.2. Presence of mild disease alleles in the Moroccan population
The (T)5 variant of intron 8 is considered as a mild splicing
CFTR mutation with incomplete penetrance. Although it is not
considered a CF-causing mutation and has no impact on genetic
counselling when found in isolation, it is frequently found in
trans with severe mutations such as F508del in CBAVD
patients [6,14-17]. Its overall prevalence in our population
(2.7%) was similar to that previously observed in series of
healthy individuals from European countries [14,15,18,19]. As
widely documented by functional and epidemiological studies,
the disease penetrance of the (T)5 variant increases with the
adjacent (TG) length [20,21]. The (TG)12(T)5 allele, whose
penetrance was assessed 78% [21], was found in four of eight
(T)5 heterozygous individuals, a result which indicates that the
Moroccan population may also be at risk for CFTR-related
disorders. Given the small size of the sample, it is not possible to
state that the proportion of (TG)12(T)5 among (T)5 alleles is
indeed more frequent in the Moroccan population than in
European or North American populations [21].
In conclusion, our preliminary study shows that the Moroccan
population is at risk for cystic fibrosis and related disorders. We
need to sensitise clinicians to the disease, and urge them to carry out
large-scale studies to identify the clinical pattern and determine
more accurately the prevalence and the molecular basis of CF in
Morocco. This could help to define diagnosis strategies and patients
care, and would also have implications for genetic counselling.
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